A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals
Public ClinicalTrials.gov record NCT03964415. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Efficacy Study of a Heterologous Vaccine Regimen of Ad26.Mos4.HIV and Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals
Study identification
- NCT ID
- NCT03964415
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Enrollment
- 3,900 participants
Conditions and interventions
Conditions
Interventions
- Ad26.Mos4.HIV Biological
- Clade C and Mosaic gp140 HIV bivalent vaccine Biological
- Placebo Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 60 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 30, 2019
- Primary completion
- Aug 9, 2023
- Completion
- Aug 9, 2023
- Last update posted
- Jul 30, 2024
2019 – 2023
United States locations
- U.S. sites
- 20
- U.S. states
- 14
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35222 | — |
| Bridge HIV | San Francisco | California | 94102 | — |
| Whitman Walker Health | Washington D.C. | District of Columbia | 20816 | — |
| University of Miami | Miami | Florida | 33136 | — |
| Orlando Immunology Center | Orlando | Florida | 32803 | — |
| Emory University Rollins School of Public Health - Ponce De Leon CRS | Atlanta | Georgia | 30322 | — |
| The Hope Clinic at Emory University | Decatur | Georgia | 30030 | — |
| University Of Illinois | Chicago | Illinois | 60612 | — |
| New Orleans Adolescent Trials Unit CRS | New Orleans | Louisiana | 70112 | — |
| Dana-Farber/Brigham and Women's Hospital | Boston | Massachusetts | 02115 | — |
| Fenway Health | Boston | Massachusetts | 02215 | — |
| Rutgers, The State University of New Jersey - The University Hospital/ACTG Network | Newark | New Jersey | 07103 | — |
| Harlem Prevention Center CRS | New York | New York | 10027 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| New York Blood Center | New York | New York | 10065 | — |
| Strong Memorial Infectious Disease | Rochester | New York | 14642 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37212 | — |
| Gordon E. Crofoot MD | Houston | Texas | 77098 | — |
| Seattle Vaccine Trials Unit | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 33 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03964415, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 30, 2024 · Synced May 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03964415 live on ClinicalTrials.gov.